Skip to main content

Table 2 Stratified analyses of the MPO-463G > A polymorphism on cancer risk by cancer type

From: Association between MPO-463G > A polymorphism and cancer risk: evidence from 60 case-control studies

Study groups A vs. G AA vs. GG AA vs. AG + GG AA + AG vs. GG
OR (95%CI) I 2 OR (95%CI) I 2 OR (95%CI) I 2 OR (95%CI) I 2
Total 0.90(0.84–0.95) 0.571 0.84(0.76–0.94) 0.417 0.87(0.78–0.97) 0.366 0.89(0.83–0.95) 0.520
Lung 0.92(0.83–1.01) 0.525 0.93(0.78–1.10) 0.481 0.95(0.80–1.12) 0.488 0.93(0.87–0.99) 0.420
Breast 0.98(0.83–1.16) 0.545 0.99(0.75–1.30) 0.441 1.00(0.76–1.32) 0.342 0.96(0.85–1.08) 0.418
Digestive 0.71(0.57–0.87) 0.694 0.63(0.37–1.05) 0.529 0.77(0.57–1.02) 0.415 0.67(0.53–0.84) 0.619
Dig tract 0.75(0.59–0.95) 0.668 0.74(0.39–1.43) 0.523 0.92(0.65–1.29) 0.449 0.72(0.56–0.92) 0.577
Dig gland 0.63(0.40–0.98) 0.700 0.41(0.23–0.72) 0.355 0.51(0.29–0.89) 0.000 0.58(0.35–0.96) 0.649
Blood 1.12(0.96–1.25) 0.431 0.96(0.63–1.58) 0.501 1.03(0.85–1.40) 0.623 1.03(0.85–1.40) 0.623